Mereo BioPharma Group (LON:MPH) Reaches New 52-Week Low at $29.75

Shares of Mereo BioPharma Group PLC (LON:MPH) reached a new 52-week low during mid-day trading on Friday . The company traded as low as GBX 29.75 ($0.39) and last traded at GBX 28 ($0.37), with a volume of 26580 shares trading hands. The stock had previously closed at GBX 34.50 ($0.45).

The company has a quick ratio of 2.18, a current ratio of 2.32 and a debt-to-equity ratio of 55.68. The firm has a market cap of $27.43 million and a price-to-earnings ratio of -0.65. The business has a 50 day moving average price of GBX 41.91 and a 200-day moving average price of GBX 54.87.

In related news, insider Richard Jones bought 25,440 shares of the stock in a transaction dated Monday, November 25th. The stock was acquired at an average price of GBX 38 ($0.50) per share, for a total transaction of £9,667.20 ($12,716.65). Also, insider Peter J. Fellner bought 23,800 shares of the stock in a transaction dated Friday, October 11th. The stock was bought at an average price of GBX 60 ($0.79) per share, with a total value of £14,280 ($18,784.53). In the last quarter, insiders bought 62,740 shares of company stock valued at $3,191,220.

About Mereo BioPharma Group (LON:MPH)

Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.

Further Reading: What is the Beige Book?

Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with's FREE daily email newsletter.